Previous 10 | Next 10 |
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical ...
Celcuity (CELC): Q1 Non-GAAP EPS of -$0.21 misses by $0.01; GAAP EPS of -$0.25 misses by $0.02.Cash and cash equivalents of $34.94M.Press Release For further details see: Celcuity EPS misses by $0.01
Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine...
MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2019, Pfizer (NYSE: PFE ) was just another pharmaceutical company. Then in 2020 into 2021, it achieved its moment of stardom with the development of its Covid-19 vaccine. It is no small feat to develop a vacc...
Are These Best Health Care Stocks To Buy In The Stock Market Today? Health care is something that everyone needs at some point in their lives. Therefore, there are always opportunities for investors in health care stocks . It doesn’t take a genius to guess that the sector...
Celcuity (CELC) presented results of studies evaluating gedatolisib, inavolisib, and navitoclax in breast and ovarian patient tumors at the American Association for Cancer Research ((AACR)) annual meeting.In the results presented, Gedatolisib inhibited nine times more signaling test activity ...
- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor - ...
Gainers: Wilhelmina International (WHLM) +44%.180 Life Sciences (ATNF) +28%.Evelo Biosciences (EVLO) +24%.Celcuity (CELC) +19%.Taysha Gene Therapies (TSHA) +17%.Nuance Communications (NUAN) +16%.Tiziana Life Sciences (TLSA) +15%.PLBY Group (PLBY) +13%.Pintec Technology (PT) +13%.Aur...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to close at record levels Friday, with the Dow Jones hitting 33,800 and the S&P 500 topping 4,100, as investors ignored co...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...